Post-transplant lymphoproliferative disorder: a review
Tóm tắt
Từ khóa
Tài liệu tham khảo
Starzl TE . Discussion of Murray JE, Wilson RE, Tilney NL et al: Five years' experience in renal transplantation with immunosuppressive drugs: survival, function, complications and the role of lymphocyte depletion by thoracic duct fistula. Ann Surg 1968; 168: 416–435.
Penn I, Hammond W, Brettschneider L et al. Malignant lymphomas in transplantation patients. Transplant Proc 1969; 1: 106–112.
Bhatia S, Ramsay NK, Steinbuch M et al. Malignant neoplasms following bone marrow transplantation. Blood 1996; 87: 3633–3639.
Nalesnik MA . Posttransplantation lymphoproliferative disorders (PTLD): current perspectives. Semin Thorac Cardiovasc Surg 1996; 8: 139–148.
Paya CV, Fung JJ, Nalesnik MA et al. Epstein–Barr virus-induced posttransplant lymphoproliferative disorders. ASTS/ASTP EBV-PTLD Task Force and The Mayo Clinic Organized International Consensus Development Meeting. Transplantation 1999; 68: 1517–1525.
Harris NL, Ferry JA, Swerdlow SH . Posttransplant lymphoproliferative disorders: summary of Society for Hematopathology Workshop. Semin Diagn Pathol 1997; 14: 8–14.
Harris NL, Jaffe ES, Diebold J et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol 1999; 17: 3835–3849.
Harris NL, Jaffe ES, Stein H et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994; 84: 1361–1392.
Epstein MA, Achong BG, Barr YM . Virus particles in cultured lymphoblasts from Burkitt's lymphoma. Lancet 1964; 1: 702–703.
Zutter MM, Martin PJ, Sale GE et al. Epstein–Barr virus lymphoproliferation after bone marrow transplantation. Blood 1988; 72: 520–529.
Shapiro RS, McClain K, Frizzera G et al. Epstein–Barr virus associated B cell lymphoproliferative disorders following bone marrow transplantation. Blood 1988; 71: 1234–1243.
Parry-Jones N, Haque T, Ismail M et al. Epstein–Barr virus (EBV) associated B-cell lymphoproliferative disease following HLA identical sibling marrow transplantation for aplastic anaemia in a patient with an EBV seronegative donor. Transplantation 1999; 67: 1373–1375.
Nalesnik MA, Makowka L, Starzl TE . The diagnosis and treatment of posttransplant lymphoproliferative disorders. Curr Probl Surg 1988; 25: 367–472.
Armitage JM, Kormos RL, Stuart RS et al. Posttransplant lymphoproliferative disease in thoracic organ transplant patients: ten years of cyclosporine-based immunosuppression. J Heart Lung Transplant 1991; 10: 877–886; discussion 886–877.
Tsai DE, Hardy CL, Tomaszewski JE et al. Reduction in immunosuppression as initial therapy for posttransplant lymphoproliferative disorder: analysis of prognostic variables and long- term follow-up of 42 adult patients. Transplantation 2001; 71: 1076–1088.
Crawford DH, Mulholland N, Iliescu V et al. Epstein–Barr virus infection and immunity in bone marrow transplant recipients. Transplantation 1986; 42: 50–54.
Lucas KG, Small TN, Heller G et al. The development of cellular immunity to Epstein–Barr virus after allogeneic bone marrow transplantation. Blood 1996; 87: 2594–2603.
Marshall NA, Howe JG, Formica R et al. Rapid reconstitution of Epstein–Barr virus-specific T lymphocytes following allogeneic stem cell transplantation. Blood 2000; 96: 2814–2821.
Small TN, Papadopoulos EB, Boulad F et al. Comparison of immune reconstitution after unrelated and related T-cell- depleted bone marrow transplantation: effect of patient age and donor leukocyte infusions. Blood 1999; 93: 467–480.
Gross TG, Steinbuch M, DeFor T et al. B cell lymphoproliferative disorders following hematopoietic stem cell transplantation: risk factors, treatment and outcome. Bone Marrow Transplant 1999; 23: 251–258.
Micallef IN, Chhanabhai M, Gascoyne RD et al. Lymphoproliferative disorders following allogeneic bone marrow transplantation: the Vancouver experience. Bone Marrow Transplant 1998; 22: 981–987.
Curtis RE, Travis LB, Rowlings PA et al. Risk of lymphoproliferative disorders after bone marrow transplantation: a multi-institutional study. Blood 1999; 94: 2208–2216.
Chiang KY, Hazlett LJ, Godder KT et al. Epstein–Barr virus-associated B cell lymphoproliferative disorder following mismatched related T cell-depleted bone marrow transplantation. Bone Marrow Transplant 2001; 28: 1117–1123.
Hauke RJ, Greiner TC, Smir BN et al. Epstein–Barr virus-associated lymphoproliferative disorder after autologous bone marrow transplantation: report of two cases. Bone Marrow Transplant 1998; 21: 1271–1274.
Shepherd JD, Gascoyne RD, Barnett MJ et al. Polyclonal Epstein–Barr virus-associated lymphoproliferative disorder following autografting for chronic myeloid leukemia. Bone Marrow Transplant 1995; 15: 639–641.
Lones MA, Kirov I, Said JW et al. Post-transplant lymphoproliferative disorder after autologous peripheral stem cell transplantation in a pediatric patient. Bone Marrow Transplant 2000; 26: 1021–1024.
Leblond V, Davi F, Charlotte F et al. Posttrans-plant lymphoproliferative disorders not associated with Epstein–Barr virus: a distinct entity? J Clin Oncol 1998; 16: 2052–2059.
Nelson BP, Nalesnik MA, Bahler DW et al. Epstein–Barr virus-negative post-transplant lymphoproliferative disorders: a distinct entity? Am J Surg Pathol 2000; 24: 375–385.
Benkerrou M, Durandy A, Fischer A . Therapy for transplant-related lymphoproliferative diseases. Hematol Oncol Clin North Am 1993; 7: 467–475.
Benkerrou M, Jais JP, Leblond V et al. Anti-B-cell monoclonal antibody treatment of severe posttransplant B- lymphoproliferative disorder: prognostic factors and long-term outcome. Blood 1998; 92: 3137–3147.
Riddler SA, Breinig MC, McKnight JL . Increased levels of circulating Epstein–Barr virus (EBV)-infected lymphocytes and decreased EBV nuclear antigen antibody responses are associated with the development of posttransplant lymphoproliferative disease in solid-organ transplant recipients. Blood 1994; 84: 972–984.
Savoie A, Perpete C, Carpentier L et al. Direct correlation between the load of Epstein–Barr virus-infected lymphocytes in the peripheral blood of pediatric transplant patients and risk of lymphoproliferative disease. Blood 1994; 83: 2715–2722.
Rooney CM, Smith CA, Ng CY et al. Use of gene-modified virus-specific T lymphocytes to control Epstein–Barr-virus-related lymphoproliferation. Lancet 1995; 345: 9–13.
Kenagy DN, Schlesinger Y, Weck K et al. Epstein–Barr virus DNA in peripheral blood leukocytes of patients with posttransplant lymphoproliferative disease. Transplantation 1995; 60: 547–554.
Lucas KG, Burton RL, Zimmerman SE et al. Semiquantitative Epstein–Barr virus (EBV) polymerase chain reaction for the determination of patients at risk for EBV-induced lymphoproliferative disease after stem cell transplantation. Blood 1998; 91: 3654–3661.
McDiarmid SV, Jordan S, Kim GS et al. Prevention and preemptive therapy of postransplant lymphoproliferative disease in pediatric liver recipients. Transplantation 1998; 66: 1604–1611.
Rooney CM, Loftin SK, Holladay MS et al. Early identification of Epstein–Barr virus-associated post-transplantation lymphoproliferative disease. Br J Haematol 1995; 89: 98–103.
Green M, Bueno J, Rowe D et al. Predictive negative value of persistent low Epstein–Barr virus viral load after intestinal transplantation in children. Transplantation 2000; 70: 593–596.
Yang J, Tao Q, Flinn IW et al. Characterization of Epstein–Barr virus-infected B cells in patients with posttransplantation lymphoproliferative disease: disappearance after rituximab therapy does not predict clinical response. Blood 2000; 96: 4055–4063.
Colby BM, Shaw JE, Elion GB et al. Effect of acyclovir [9-(2-hydroxyethoxymethyl)guanine] on Epstein–Barr virus DNA replication. J Virol 1980; 34: 560–568.
Faller DV, Mentzer SJ, Perrine SP . Induction of the Epstein–Barr virus thymidine kinase gene with concomitant nucleoside antivirals as a therapeutic strategy for Epstein–Barr virus-associated malignancies. Curr Opin Oncol 2001; 13: 360–367.
Starzl TE, Nalesnik MA, Porter KA et al. Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy. Lancet 1984; 1: 583–587.
Davis CL, Wood BL, Sabath DE . Interferon-alpha treatment of posttransplant lymphoproliferative disorder in recipients of solid organ transplants. Transplantation 1998; 66: 1770–1779.
Faro A, Kurland G, Michaels MG et al. Interferon-alpha affects the immune response in post-transplant lymphoproliferative disorder. Am J Respir Crit Care Med 1996; 153: 1442–1447.
Haddad E, Paczesny S, Leblond V et al. Treatment of B-lymphoproliferative disorder with a monoclonal anti-interleukin-6 antibody in 12 patients: a multicenter phase 1-2 clinical trial. Blood 2001; 97: 1590–1597.
Swinnen LJ, Mullen GM, Carr TJ et al. Aggressive treatment for postcardiac transplant lymphoproliferation. Blood 1995; 86: 3333–3340.
Mamzer-Bruneel MF, Lome C, Morelon E et al. Durable remission after aggressive chemotherapy for very late post- kidney transplant lymphoproliferation: a report of 16 cases observed in a single center. J Clin Oncol 2000; 18: 3622–3632.
Kook H, Goldman F, Padley D et al. Reconstruction of the immune system after unrelated or partially matched T-cell-depleted bone marrow transplantation in children: immunophenotypic analysis and factors affecting the speed of recovery. Blood 1996; 88: 1089–1097.
Kuzushima K, Kimura H, Hoshino Y et al. Longitudinal dynamics of Epstein–Barr virus-specific cytotoxic T lymphocytes during posttransplant lymphoproliferative disorder. J Infect Dis 2000; 182: 937–940.
Khatri VP, Baiocchi RA, Peng R et al. Endogenous CD8+ T cell expansion during regression of monoclonal EBV- associated posttransplant lymphoproliferative disorder. J Immunol 1999; 163: 500–506.
Porter DL, Orloff GJ, Antin JH . Donor mononuclear cell infusions as therapy for B-cell lymphoproliferative disorder following allogeneic bone marrow transplant. Transplant Sci 1994; 4: 12–14; discussion 14–16.
Papadopoulos EB, Ladanyi M, Emanuel D et al. Infusions of donor leukocytes to treat Epstein–Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation. New Engl J Med 1994; 330: 1185–1191.
Gustafsson A, Levitsky V, Zou JZ et al. Epstein–Barr virus (EBV) load in bone marrow transplant recipients at risk to develop posttransplant lymphoproliferative disease: prophylactic infusion of EBV-specific cytotoxic T cells. Blood 2000; 95: 807–814.
Rooney CM, Smith CA, Ng CY et al. Infusion of cytotoxic T cells for the prevention and treatment of Epstein–Barr virus-induced lymphoma in allogeneic transplant recipients. Blood 1998; 92: 1549–1555.
Wagner HJ, Rooney CM, Heslop HE . Diagnosis and treatment of posttransplantation lymphoproliferative disease after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2002; 8: 1–8.
Emanuel DJ, Lucas KG, Mallory Jr GB et al. Treatment of posttransplant lymphoproliferative disease in the central nervous system of a lung transplant recipient using allogeneic leukocytes. Transplantation 1997; 63: 1691–1694.
Gottschalk S, Ng CY, Perez M et al. An Epstein–Barr virus deletion mutant associated with fatal lymphoproliferative disease unresponsive to therapy with virus-specific CTLs. Blood 2001; 97: 835–843.
Nalesnik MA, Rao AS, Zeevi A et al. Autologous lymphokine-activated killer cell therapy of lymphoproliferative disorders arising in organ transplant recipients. Transplant Proc 1997; 29: 1905–1906.
Haque T, Amlot PL, Helling N et al. Reconstitution of EBV-specific T cell immunity in solid organ transplant recipients. J Immunol 1998; 160: 6204–6209.
Frizzera G, Hanto DW, Gajl-Peczalska KJ et al. Polymorphic diffuse B-cell hyperplasias and lymphomas in renal transplant recipients. Cancer Res 1981; 41: 4262–4279.
Knowles DM, Cesarman E, Chadburn A et al. Correlative morphologic and molecular genetic analysis demonstrates three distinct categories of posttransplantation lymphoproliferative disorders. Blood 1995; 85: 552–565.
Darenkov IA, Marcarelli MA, Basadonna GP et al. Reduced incidence of Epstein–Barr virus-associated posttransplant lymphoproliferative disorder using preemptive antiviral therapy. Transplantation 1997; 64: 848–852.
Davis CL, Harrison KL, McVicar JP et al. Antiviral prophylaxis and the Epstein Barr virus-related post- transplant lymphoproliferative disorder. Clin Transplant 1995; 9: 53–59.
Fischer A, Blanche S, Le Bidois J et al. Anti-B-cell monoclonal antibodies in the treatment of severe B-cell lymphoproliferative syndrome following bone marrow and organ transplantation. N Engl J Med 1991; 324: 1451–1456.
Faye A, Van Den Abeele T, Peuchmaur M et al. Anti-CD20 monoclonal antibody for post-transplant lymphoproliferative disorders. Lancet 1998; 352: 1285.
Kuehnle I, Huls MH, Liu Z et al. CD20 monoclonal antibody (rituximab) for therapy of Epstein–Barr virus lymphoma after hemopoietic stem-cell transplantation. Blood 2000; 95: 1502–1505.
Horowitz SM, Tsai DE, Twist C et al. Rituximab is effective therapy for post transplant lymphoproliferative disorder (PTLD) not responding to reduction in immunosuppression: a prospective trial in adults and children. Proceedings of ASCO 2001; 20: 284a.
Bonini C, Ferrari G, Verzeletti S et al. HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia. Science 1997; 276: 1719–1727.
McGuirk JP, Seropian S, Howe G et al. Use of rituximab and irradiated donor-derived lymphocytes to control Epstern-Barr virus-associated lymphoproliferation in patients undergoing related haplo-identical stem cell transplantation. Bone Marrow Transplant 1999; 24: 1253–1258.